These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1377 related items for PubMed ID: 17875764

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
    Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG.
    Clin Cancer Res; 2005 Jun 01; 11(11):4037-43. PubMed ID: 15930338
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy.
    Bianco FJ, Scardino PT, Stephenson AJ, Diblasio CJ, Fearn PA, Eastham JA.
    Int J Radiat Oncol Biol Phys; 2005 Jun 01; 62(2):448-53. PubMed ID: 15890586
    [Abstract] [Full Text] [Related]

  • 8. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
    Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H.
    J Urol; 2003 Nov 01; 170(5):1872-6. PubMed ID: 14532796
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
    Freedland SJ, Hotaling JM, Fitzsimons NJ, Presti JC, Kane CJ, Terris MK, Aronson WJ, Amling CL.
    Eur Urol; 2008 Apr 01; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
    [Abstract] [Full Text] [Related]

  • 12. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy.
    Witherspoon LR, Lapeyrolerie T.
    J Urol; 1997 Apr 01; 157(4):1322-8. PubMed ID: 9120931
    [Abstract] [Full Text] [Related]

  • 13. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR, Betancourt JE.
    Mol Urol; 2000 Apr 01; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [Abstract] [Full Text] [Related]

  • 14. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
    Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H.
    J Urol; 2000 Jul 01; 164(1):101-5. PubMed ID: 10840432
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
    Huang SP, Huang CY, Wang JS, Liu CC, Pu YS, Yu HJ, Yu CC, Wu TT, Huang CH, Wu WJ, Chou YH, Wu MT.
    Clin Cancer Res; 2007 Nov 15; 13(22 Pt 1):6632-8. PubMed ID: 18006764
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.
    San Francisco IF, Regan MM, Olumi AF, DeWolf WC.
    J Urol; 2004 Apr 15; 171(4):1492-9. PubMed ID: 15017206
    [Abstract] [Full Text] [Related]

  • 19. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
    Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, Huland E, Scardino PT, Kattan MW, Huland H.
    J Urol; 2002 Mar 15; 167(3):1306-9. PubMed ID: 11832719
    [Abstract] [Full Text] [Related]

  • 20. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
    Tahir SA, Frolov A, Hayes TG, Mims MP, Miles BJ, Lerner SP, Wheeler TM, Ayala G, Thompson TC, Kadmon D.
    Clin Cancer Res; 2006 Aug 15; 12(16):4872-5. PubMed ID: 16914574
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 69.